Adis, a Wolters Kluwer Business, Auckland, New Zealand.
Am J Cardiovasc Drugs. 2010;10(1):65-71. doi: 10.2165/10489040-000000000-00000.
Regadenoson is an adenosine A(2A) receptor agonist approved for use as a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Regadenoson causes a rapid increase in coronary blood flow, which is sustained for a short duration. In two phase III trials in patients with known or suspected coronary artery disease who were indicated for pharmacologic stress myocardial perfusion imaging, the agreement rate (in detecting reversible perfusion defects) between sequential adenosine-regadenoson scan images was noninferior to that between sequential adenosine-adenosine scan images. Regadenoson, compared with adenosine, was associated with a faster and greater peak increase in heart rate, but a slower return to baseline. The SBP and DBP decreased slightly with both agents; recovery to baseline levels was again faster with adenosine than with regadenoson. Regadenoson appeared to be generally well tolerated, with most adverse events beginning soon after administration and resolving within approximately 15 minutes. No unexpected treatment-emergent ECG changes occurred with regadenoson in the phase III trials.
雷加腺苷是一种腺嘌呤 A（2A）受体激动剂，获批用于不能进行充分运动应激的患者放射性核素心肌灌注成像的药物应激剂。雷加腺苷可引起冠状动脉血流的快速增加，并持续短暂时间。在两项三期临床试验中，患有已知或疑似冠状动脉疾病且需要药物应激心肌灌注成像的患者中，连续腺苷-雷加腺苷扫描图像之间的（检测可逆灌注缺陷）一致性率不劣于连续腺苷-腺苷扫描图像之间的一致性率。与腺苷相比，雷加腺苷与更快和更大的心率峰值增加相关，但恢复到基线的速度较慢。两种药物均使 SBP 和 DBP 略有下降；再次，与雷加腺苷相比，腺苷恢复到基线水平的速度更快。雷加腺苷似乎总体上耐受良好，大多数不良事件在给药后不久发生，并在大约 15 分钟内解决。在三期试验中，雷加腺苷未发生意外的治疗中出现的心电图变化。
